BioLineRx, a clinical-stage biopharmaceutical company, will release its Q1 2026 financial results on May 27, 2026. Analysts expect an earnings loss of $1.04 per share and revenue of $343,000, reflecting ongoing development costs typical for its growth phase. Despite the loss and a negative P/E ratio, the company shows solid financial health with a current ratio of 1.95 and a manageable debt-to-equity ratio of 0.56. Investors will also hear from CEO Philip Serlin in a conference call following the report, providing insights into the company’s progress in oncology and rare disease treatments.
Google Cloud Security used the Instruqt platform to train over 150 professionals on Agentic AI during the Google Next 2026 conference. Each participant worked in a dedicated Google Cloud Vertex AI environment to build and explore AI agents hands-on, ...
At Google Next 2026, Google Cloud Security used the Instruqt platform to train over 150 practitioners on Agentic AI. Each participant received a dedicated Vertex AI environment to build their own AI agents hands-on, moving beyond slide-based demos. T...
At the 2026 Google Next conference, Google Cloud Security used the Instruqt platform to provide hands-on Agentic AI training to over 150 practitioners. Each participant received a dedicated Google Cloud Vertex AI environment to build and explore AI a...
At Google Next 2026, Google Cloud Security used the Instruqt platform to train over 150 professionals in agentic AI capabilities. Each participant received a dedicated Google Cloud Vertex AI environment to build and explore AI agents hands-on, moving...
In May 2026, seven small-cap stocks in the Russell 2000 more than doubled the return of Micron Technology, which gained 46%. Leading performers included Hyliion Holdings (+213.6%) after strong revenue growth and U.S. Navy trials, and agilon health (+...
